AVODART Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Avodart, and when can generic versions of Avodart launch?
Avodart is a drug marketed by Waylis Therap and is included in one NDA.
The generic ingredient in AVODART is dutasteride. There are eighteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the dutasteride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avodart
A generic version of AVODART was approved as dutasteride by BARR on December 21st, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AVODART?
- What are the global sales for AVODART?
- What is Average Wholesale Price for AVODART?
Summary for AVODART
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 39 |
| Patent Applications: | 3,998 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AVODART |
| What excipients (inactive ingredients) are in AVODART? | AVODART excipients list |
| DailyMed Link: | AVODART at DailyMed |
Recent Clinical Trials for AVODART
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Radboud University Medical Center | Phase 2 |
| Dongkook Pharmaceutical Co., Ltd. | Phase 3 |
| Addpharma Inc. | Phase 1 |
Pharmacology for AVODART
| Drug Class | 5-alpha Reductase Inhibitor |
| Mechanism of Action | 5-alpha Reductase Inhibitors |
Paragraph IV (Patent) Challenges for AVODART
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AVODART | Capsules | dutasteride | 0.5 mg | 021319 | 1 | 2007-10-29 |
US Patents and Regulatory Information for AVODART
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Waylis Therap | AVODART | dutasteride | CAPSULE;ORAL | 021319-001 | Nov 20, 2001 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AVODART
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Waylis Therap | AVODART | dutasteride | CAPSULE;ORAL | 021319-001 | Nov 20, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Waylis Therap | AVODART | dutasteride | CAPSULE;ORAL | 021319-001 | Nov 20, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Waylis Therap | AVODART | dutasteride | CAPSULE;ORAL | 021319-001 | Nov 20, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AVODART
See the table below for patents covering AVODART around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Finland | 961232 | ⤷ Sign Up | |
| African Regional IP Organization (ARIPO) | 9400669 | ⤷ Sign Up | |
| Germany | 69407978 | ⤷ Sign Up | |
| Luxembourg | 91027 | ⤷ Sign Up | |
| Hungary | 9600643 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 9507927 | ⤷ Sign Up | |
| South Africa | 9407119 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AVODART
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0719278 | SPC/GB03/018 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117 |
| 0719278 | PA 2003 007, C 0719278 /L | Lithuania | ⤷ Sign Up | |
| 0719278 | SPC009/2005 | Ireland | ⤷ Sign Up | SPC009/2005: 20060316, EXPIRES: 20170718 |
| 0719278 | C300122 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 28317RVG 28318 2002161216; FIRST REGISTRATION: 1787117872 2002190719 |
| 0719278 | 300122 | Netherlands | ⤷ Sign Up | |
| 0719278 | 03C0030 | France | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE; NAT. REGISTRATION NO/DATE: NL 28 131 20030327; FIRST REGISTRATION: SE - 17 871 20020719 |
| 0719278 | PA2003007,C0719278 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
